Guideline for the clinical use and dispensing of thalidomide.


In the 1 960s thalidomide virtually disappeared from clinical use after it was demonstrated that it is both a causative agent of severe irreversible peripheral neuropathyl ,2 and a human teratogen. 3,4 Currently in the UK there are no product licences for thalidomide but it can be prescribed on a 'named patient' basis in accordance with Section 9( 1 ) of… (More)


  • Presentations referencing similar topics